Humira's US biosimilar share proved that a single PBM formulary decision, not price competition, can break even the most rebate-protected biologic franchise — and Keytruda's ~$35B 2028 patent cliff and Eylea's already-expired core patent mean the next two proof points are now dated, not hypothetical.
📈 What changed: Jun 4, 2026: Alvotech resubmitted its FDA Biologics License Application for AVT06 (its Eylea/aflibercept biosimilar, partnered with Teva) after a Dec 2025 Complete Response Letter…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 82/100 | A scaled, commercial market for the flagship molecule (Humira); Keytruda/Eylea biosimilars still queuing behind settlements. |
| Evidence Strength higher is better · high confidence | 80/100 | Corroborated across a Tier-1 industry report and multiple companies' own financial disclosures. |
| Commercial Proximity higher is better · high confidence | 78/100 | Recurring commercial revenue is already at scale for the largest makers; the near-term wedge is proven, not theoretical. |
| Capital & Policy Support higher is better · high confidence | 40/100 | Regulatory pathway and payer/reimbursement dynamics drive this theme far more than public funding or a binding mandate. |
| Crowding Risk lower is better · high confidence | 38/100 | A fragmented, company-specific story rather than a single owned or ETF-flooded trade. |
| Reflexivity Risk lower is better · high confidence | 40/100 | Scaled leaders are earnings-grounded; smaller pure-plays carry real capital-markets dependence. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 11 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.